Samsung Bioepis Biosimilars Report Slams ‘Stagnant’ US Adalimumab Uptake

Figures From Q4 Reveal Humira Rivals Have Captured Just 2% Of The Market

In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.

Pie Chart Showing 2% Share, Infographic
Humira biosimilars have so far captured just 2% of the US market • Source: Shutterstock

Six months after the launch of multiple Humira (adalimumab) biosimilars in the US, and nearly a year after Amgen introduced the first biosimilar rival to the top-selling brand, biosimilar adoption “remains stagnant,” thereby “delaying an opportunity for major financial relief to the US healthcare system,” according to the latest figures and commentary from Samsung Bioepis.

[Sidebar#GB152818]

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.